Baseline clinical manifestations in and treatments received within the first year by 223 patients of the Registro Español de Lupus Eritematoso Sistémico (RELES) cohort
| N (%) | |
|---|---|
| Clinical manifestations | |
| Malar rash | 55 (25%) |
| Discoid rash | 17 (8%) |
| Subacute cutaneous lupus | 29 (13%) |
| Cutaneous vasculitis | 8 (4%) |
| Arthritis | 98 (44%) |
| Lupus nephritis | 47 (21%) |
| Class I | 2 (1%) |
| Class II | 3 (1.5%) |
| Class III | 5 (2%) |
| Class IV | 24 (11%) |
| Class V | 6 (3%) |
| No biopsy | 7 (4%) |
| Pleuritis | 28 (13%) |
| Pericarditis | 25 (11%) |
| Haemolytic anaemia | 19 (9%) |
| Thrombocytopenia | 32 (14%) |
| Venous thromboembolism | 22 (10%) |
| Stroke | 5 (2%) |
| Treatments | |
| Prednisone | 144 (65%) |
| HCQ | 182 (81%) |
| Pulse methyl-prednisolone | 34 (15%) |
| Any immunosuppressive drug | 88 (39%) |
| Cyclophosphamide | 26 (12%) |
| Azathioprine | 32 (14%) |
| Methotrexate | 20 (9%) |
| Mycophenolate (sodium or mofetil) | 42 (19%) |
| Tacrolimus | 1 (0.5%) |
HCQ, hydroxychloroquine.